XM does not provide services to residents of the United States of America.

G
G

GSK

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 2 hours ago

GSK Says Wendy Becker To Join Board As Non-Executive Director

BRIEF-GSK Says Wendy Becker To Join Board As Non-Executive Director Sept 27 (Reuters) - GSK plc GSK.L : GSK PLC - DIRECTORATE CHANGE GSK - WENDY BECKER TO JOIN BOARD AS NON-EXECUTIVE DIRECTOR GSK: WENDY BECKER WILL JOIN BOARD OF COMPANY AS A NON-EXECUTIVE DIRECTOR WITH EFFECT FROM 1 OCTOBER 2023. GSK: ANNOUNCES WENDY BECKER TO JOIN BOARD AS NON-EXE
G
Reuters - 1 day ago

Gsk Announces Largest Private Financial Contribution To Cihr's Team Grants Initiative Addressing Threats To Canadian Lung Health

BRIEF-Gsk Announces Largest Private Financial Contribution To Cihr's Team Grants Initiative Addressing Threats To Canadian Lung Health Sept 26 (Reuters) - GSK plc GSK.L : GSK ANNOUNCES LARGEST PRIVATE FINANCIAL CONTRIBUTION TO CIHR'S TEAM GRANTS INITIATIVE ADDRESSING THREATS TO CANADIAN LUNG HEALTH GSK - INVESTING $2 MILLION IN RESEARCH TO ADDRESS
G
Reuters - 2 days ago

Scynexis shares tumble on recall of antifungal drug

BUZZ-Scynexis shares tumble on recall of antifungal drug ** Shares of drugmaker Scynexis Inc SCYX.O slump 32% to $2.1 in premarket trading ** Says to recall antifungal drug Brexafemme, pause studies due to potential risk of cross contamination with another compound ** Says became aware after a review by partner GSK that substances used to make beta
G
Reuters - 2 days ago

Scynexis to recall partnered antifungal on cross contamination risk

UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk Adds GSK response in paragraph 8, updates share movement By Manas Mishra Sept 25 (Reuters) - Scynexis SCYX.O said on Monday it would voluntarily recall its antifungal pill, which it has licensed to GSK GSK.L , due to risk of cross-contamination with a potential allergy-inducing compound, sending the drugmaker's shares tumbling over 30%.
G
Reuters - 2 days ago

Scynexis Inc Scynexis Is Recalling Brexafemme(Reg) (Ibrexafungerp Tablets) From Market

BRIEF-Scynexis Inc Scynexis Is Recalling Brexafemme(Reg) (Ibrexafungerp Tablets) From Market Sept 25 (Reuters) - GSK plc GSK.L : SCYNEXIS INC: SCYNEXIS IS RECALLING BREXAFEMME(REG) (IBREXAFUNGERP TABLETS) FROM MARKET SCYNEXIS - NOT KNOWN WHETHER ANY IBREXAFUNGERP HAS BEEN CONTAMINATED WITH A BETA-LACTAM COMPOUND SCYNEXIS - BECAME AWARE NON-ANTIBACT
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.